title: In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.
abstract: BRAF(V600E) mutation has been frequently reported in different types of melanocytic lesions, but its role in melanomagenesis is poorly understood, having been associated with either the proliferative-induced MAPK pathway activation or the acquisition of oncogene-driven senescence. The presence of BRAF alterations has been related to sun exposure, although the molecular mechanisms underlying this event are only partly known. To elucidate the relationships among BRAF/NRAS alterations, MAPK pathway activation, and sun exposure, we examined 22 acquired nevi and 18 cutaneus melanomas from 38 patients. Microdissected tissues from each lesion were subjected to BRAF/NRAS mutation analysis by sequencing, allele-specific PCR and pyrosequencing assay. The same lesions were also examined for the expression of phosphorylated ERK1/2. Phototype and an accurate history of sun exposure were evaluated for each patient. BRAF(V600E) mutation was detected in 50% of the acquired nevi and in 70% of the cutaneus melanomas in the absence of NRAS alterations. The fraction of alleles carrying BRAF(V600E) substitution was variable but strongly associated with sun exposure. In contrast, no relationship was evidenced between the presence of this mutation and patients' phototype, phosphorylated ERK1/2 expression, or Clark's level. Our findings indicate that in melanocytic lesions, BRAF(V600E) mutation can affect a subset of the cells and is associated with the type and quantity of sun exposure. This mutation is independent of the nevo-melanoma progression and unrelated to ERK phosphorylation, suggesting that alternative mechanisms to the MAPK activation are also involved in this type of transformation.
authors.affiliation: Unit of Pathology, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy. tiziana.venesio@ircc.it
authors.forename: Tiziana
authors.initials: T
authors.lastname: Venesio
authors.forename: Giovanna
authors.initials: G
authors.lastname: Chiorino
authors.forename: Antonella
authors.initials: A
authors.lastname: Balsamo
authors.forename: Alessandro
authors.initials: A
authors.lastname: Zaccagna
authors.forename: Consalvo
authors.initials: C
authors.lastname: Petti
authors.forename: Maria
authors.initials: M
authors.lastname: Scatolini
authors.forename: Alberto
authors.initials: A
authors.lastname: Pisacane
authors.forename: Ivana
authors.initials: I
authors.lastname: Sarotto
authors.forename: Franco
authors.initials: F
authors.lastname: Picciotto
authors.forename: Mauro
authors.initials: M
authors.lastname: Risio
mesh_terms: D000328:Adult; D000368:Aged; D001483:Base Sequence; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000209:etiology / Q000235:genetics* / Q000378:metabolism; D042282:Microdissection; D008875:Middle Aged; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D008969:Molecular Sequence Data; D009154:Mutation; D009508:Nevus, Pigmented / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012878:Skin Neoplasms / Q000209:etiology / Q000235:genetics* / Q000378:metabolism; D013472:Sunlight / Q000009:adverse effects*
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048049:Extracellular Signal-Regulated MAP Kinases; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3